AG
ACET icon

Artal Group’s Adicet Bio ACET Stock Holding History

Artal Group’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-8,083
Closed -$1.82M – 149
2020
Q4 		$1.82M Hold
8,083
– – 0.04% 123
2020
Q3 		$1.54M Sell
8,083
-426
-5% -$108K 0.04% 125
2020
Q2 		$2.05M Buy
+8,509
New +$1.67M 0.06% 124
2019
Q4 		– Sell
-4,464
Closed -$4.42M – 97
2019
Q3 		$4.42M Buy
4,464
+1,250
+39% +$1.4M 0.18% 76
2019
Q2 		$3.67M Sell
3,214
-357
-10% -$324K 0.15% 87
2019
Q1 		$2.73M Hold
3,571
– – 0.11% 91
2018
Q4 		$3.45M Sell
3,571
-893
-20% -$1.18M 0.13% 80
2018
Q3 		$7.57M Sell
4,464
-447
-9% -$583K 0.2% 63
2018
Q2 		$5.03M Buy
4,911
+893
+22% +$961K 0.11% 68
2018
Q1 		$4.31M Buy
+4,018
New +$7.37M 0.05% 78

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Artal Group's ACET Position: Q1 2021 in Review

Artal Group sold out of Adicet Bio (ACET) in Q1 2021, closing a stake of 8,083 shares — an estimated $1.82M sold.

Artal Group first reported a position in ACET in Q1 2018 and held it in 10 quarters. The position peaked at $7.57M in Q3 2018. 53 funds tracked by Wall St. Rank hold ACET as of Q1 2021.

  • Artal Group reported no remaining Adicet Bio position as of Q1 2021 after selling out during the quarter.
  • Artal Group sold 8,083 Adicet Bio shares in Q1 2021, an estimated $1.82M.
  • Artal Group first reported a position in Adicet Bio in Q1 2018 and held it in 10 quarters.
  • Artal Group's Adicet Bio position peaked at $7.57M in Q3 2018.
  • 53 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2021.

Based on Artal Group's 13F filing for Q1 2021, filed 14 May 2021.